QFITLIA
Live / Registered — Registered (as of 03 Jun 2025)
What this means for you
Registered since 03 Jun 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98054571
- Registration number
- 7820002
- Mark type
- Design + words
- Filed
- 22 Jun 2023
- Published for opposition
- 02 Apr 2024
- Registered
- 03 Jun 2025
- Attorney of record
- Karen Lim
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and diseases of the central nervous system; pharmaceutical preparations for the treatment of cancer, thrombosis, and respiratory diseases; pharmaceutical preparations for the treatment of rare blood disorders; pharmaceutical preparations for the prevention and treatment of infectious diseases, namely, viral and bacterial infections; pharmaceutical preparations for the treatment of lysosomal storage diseases
Owner
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
Prosecution history
- 03 Jun 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 03 Jun 2025 — REGISTERED-PRINCIPAL REGISTER
- 12 May 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 12 May 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 22 Apr 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 15 Apr 2025 — USE AMENDMENT FILED
- 15 Apr 2025 — TEAS STATEMENT OF USE RECEIVED
- 10 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Feb 2025 — SOU EXTENSION 1 GRANTED
- 18 Nov 2024 — SOU EXTENSION 1 FILED
- 07 Feb 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 18 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 04 Jun 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Apr 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Apr 2024 — PUBLISHED FOR OPPOSITION